Member Info for Digger01

Typo I would suggest! 21.6p?

Well that’s no surprise that we have to pay substantial royalties. They had a good opportunity to buy this company but missed the opportunity.
Another poor decision.

Crazy reaction to great results and Divi announcement.

Good information guys. On a different note if we can contain the loss to around 5m fir Q2, that would be a good step forward in sales volume. It would also look very good in terms of not requiring a fund raise.
IMHO that will hurt the shorters.
We shall see, but I may well take another punt at this level.

Where does it mention scale up in that twitter link?
Also the service provider is FDA inspected! I assume that this is just like a third party accreditation, which “possibly” the FDA may require Angle to select a supplier with? However, I fail to see how it can be assumed that approval is in the bag, based on that tweet. I am not doubting the approval prospects, just my opinion of the tweet.

Excellent information which is much appreciated.
The step forward with lab accreditation is also another key piece in the puzzle. Services can be offered with or without FDA approval, however, the scale up plans require it. The risk is still high here, but the company have focused and liaised with FDA for many years now and hopefully the perseverance and obvious due diligence will be rewarded for this clearly needed tech.

Well if any of those negatives become positive via results! Then this could rise as quick as the fall!
Here’s to hoping the management are right. Either way, these clever shorters will no doubt make a fortune both ways.

Thank you for the clarity luckcounts.
Still a compelling investment.

I also not that the West Gharib is deemed as high margin with more wells coming on line, so even at an estimated 1250bpd, this should lead to £40m revenue.
I don’t get this SP either, unless sentiment is based on previous performance and lack of trust?

2022 guidance of circa 2500 bpd.
Is that net to SDX, or do we earn 50% of that?

Thanks all for the feedback.
I am sure that we will hear soon as regards the FDA decision and hope it’s positive. It’s been a very long road working towards approval, with a lot of due diligence and hard work. The FDA have been consulted most of the way and we also have excellent independent peer reviews, which bodes well.

Does anyone have L2 access to give better clarity with regards to the multiple Unknown trades? Buys or sells?

This implies the opposite.
https://www.reuters.com/business/finance/russian-central-bank-resume-gold-purchases-domestic-market-monday-2022-02-27/

Having reviewed details regarding the submission, posted via RNS since early 2019, it is clear that the company has been on ongoing dialogue with FDA and has done an excellent job with due diligence, in order to minimise the risk. Secondly they have pressed on with Lab services based on the presentations, which are already generating revenue. I would assume (Like RENX) that they don’t actually need FDA approval to be successful, but the whole process would happen a lot faster and with greater confidence.

I did ask this earlier, but never had any comments which would be appreciated.

Please advise if I am missing something here.
Oct interims gave an adjusted profit of 2.6m for H1.
We are now looking at an adjusted forecast of a min of £7.5m less 30% for the year which means H2 broadly equal H1?

Good summary Burry.
Please advise if I am missing something here.
Oct interims gave an adjusted profit of 2.6m for H1.
We are now looking at an adjusted forecast of a min of £7.5m less 30% for the year which means H2 broadly equal H1?
If so, why the carnage?

What’s happening with LSN and Stonechecker?
No mention of these two products for some period of time?

My fag packet estimates. Comments as regards outgoings and US revenue appreciated.
So FY20 they spent circa 12m
FY21H1. Circa 9m
FY21H2. Circa 12m
What will the outgoings be in 2022? A bit of a guess at 16m? As many upfront US costs will have been met.
Eu Renenue maybe 2.5m
Pessimistic view of US sales based on
Q1 4000 x $250
Q2 7000 x $250
Q3 12000 x $250
Q4 20000 x $250

Total revenue of 10.75m US and 2.25m EU generating a loss of 3m?
Hardman report suggests revenue of £35m so 3 x greater than my estimate above, however, they still forecast 4.5m loss, so their outgoings forecast are double mine. So the magnitude of likely loss depends on the Actual costs of sales employment and marketing and of course how many prescriptions are achieved. Touch and go as to whether more funding will be required.
So we need good solid sales progression and I will at least wait for Q1 update before topping up.
A good first square on the board but we could do with landing a ladder sooner please.

Considering it kicked off a lot earlier than US sales, why are EU sales so low?

Maybe it was trading at too much of a premium to current NAV and presumably some possible profit taking. Still a very solid investment with rising Divi.